FOCUSED ON WOMEN'S HEALTH and hormone-sensitive cancer for healthy aging worldwide

Discover our research

Our solution

A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values.

Find out about Intrarosa™

Our goal as a Quebec company

 

Our main goal is to offer all women in the world, in addition to the treatment of vaginal atrophy, the benefits of effective, physiological and non-negative treatments for all menopausal problems, including hot flashes, bone loss and muscle loss.

Research and Development

Latest News

Read the news

ENDOCEUTICS ANNOUNCES ACQUISITION OF THE INTRAROSA® U.S. COMMERCIAL RIGHTS BY MILLICENT PHARMA

May 27, 2020

Quebec City, Canada; Endoceutics announces that the U.S. commercial rights for its flagship product, INTRAROSA®, were transferred to Millicent Pharma following a divestiture process announced in January 2020 by AMAG Pharmaceuticals.

ENDOCEUTICS RECEIVES HEALTH CANADA APPROVAL FOR INTRAROSA

November 6, 2019

Quebec City, Canada; Endoceutics is happy to announce the approval of INTRAROSA by Health Canada for the treatment of postmenopausal vulvovaginal atrophy.

Endoceutics to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

April 25, 2019

Québec City, Canada; Endoceutics announced today that Dennis Turpin, President and Chief Executive Officer of Endoceutics, is scheduled to present an overview of the company at the Bloom Burton & Co. Healthcare Investor Conference.